Frontotemporal Dementia

Migration, Crosslink

📖

Frontotemporal Dementia

active

wiki page Created: 2026-04-02T07:20:13 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-diseases-frontotemporal-dementia

📖 Wiki Page

disease3759 wordssynced 2026-04-02

Frontotemporal Dementia (FTD)

Introduction

Frontotemporal Dementia (FTD) is a group of neurodegenerative disorders characterized by progressive degeneration of the frontal and temporal lobes of the brain. It is the second most common cause of early-onset dementia after Alzheimer's Disease, typically affecting individuals between 45-65 years of age. FTD encompasses a spectrum of clinical syndromes, including behavioral variant FTD (bvFTD) and primary progressive aphasia (PPA) variants, each with distinct clinical presentations and underlying pathologies. [@heneka2023]

Unlike Alzheimer's Disease, which primarily affects memory, FTD often presents with changes in personality, behavior, and language abilities, reflecting the regional distribution of neurodegeneration in the frontal and temporal cortices. The disease is pathologically heterogeneous, with approximately 50% of cases showing [tau protein](/proteins/tau) inclusions (FTLD-tau) and 45% showing TDP-43 inclusions (FTLD-TDP), while a smaller subset exhibits FUS pathology. [@gao2024]

Overview

Frontotemporal Dementia represents a clinically and pathologically diverse group of disorders that result from degeneration of the anterior cerebral hemispheres. The estimated prevalence is 10-20 per 100,000 individuals aged 45-64, making it a significant cause of early-onset neurodegenerative dementia. [@li2024]

...

Frontotemporal Dementia (FTD)

Introduction

Frontotemporal Dementia (FTD) is a group of neurodegenerative disorders characterized by progressive degeneration of the frontal and temporal lobes of the brain. It is the second most common cause of early-onset dementia after Alzheimer's Disease, typically affecting individuals between 45-65 years of age. FTD encompasses a spectrum of clinical syndromes, including behavioral variant FTD (bvFTD) and primary progressive aphasia (PPA) variants, each with distinct clinical presentations and underlying pathologies. [@heneka2023]

Unlike Alzheimer's Disease, which primarily affects memory, FTD often presents with changes in personality, behavior, and language abilities, reflecting the regional distribution of neurodegeneration in the frontal and temporal cortices. The disease is pathologically heterogeneous, with approximately 50% of cases showing [tau protein](/proteins/tau) inclusions (FTLD-tau) and 45% showing TDP-43 inclusions (FTLD-TDP), while a smaller subset exhibits FUS pathology. [@gao2024]

Overview

Frontotemporal Dementia represents a clinically and pathologically diverse group of disorders that result from degeneration of the anterior cerebral hemispheres. The estimated prevalence is 10-20 per 100,000 individuals aged 45-64, making it a significant cause of early-onset neurodegenerative dementia. [@li2024]

FTD is often inherited in an autosomal dominant pattern in 20-30% of cases, with three major causal genes: [MAPT](/proteins/mapt-protein) (microtubule-associated protein tau), [GRN](/proteins/grn-protein) (progranulin), and [C9orf72](/proteins/c9orf72-protein) (chromosome 9 open reading frame 72). These genetic forms typically have earlier onset and may present with overlapping features with ALS in [C9orf72](/entities/c9orf72) carriers. [@bennett2024]

The clinical syndromes within the FTD spectrum include:

Behavioral Variant FTD (bvFTD): Characterized by disinhibition, apathy, loss of empathy, compulsivity, and dietary changes
Semantic Variant Primary Progressive Aphasia (svPPA): Progressive loss of word and object meaning
Nonfluent/agrammatic Variant PPA (nfvPPA): Grammatical errors and effortful speech
Logopenic Variant PPA (lvPPA): Word-finding pauses and memory lapses

Epidemiology

Frontotemporal dementia accounts for 10-20% of all dementia cases and up to 50% of dementia cases with onset before 65 years. [@li2024] The estimated prevalence is:

Age-specific: 10-20 per 100,000 in individuals aged 45-64 years
Gender distribution: Slight male predominance (1.5:1) in bvFTD
Onset: Typically 45-65 years, though ranges from 20-80 years
Survival: Median survival 6-11 years from symptom onset

Approximately 20-30% of FTD cases have a family history consistent with autosomal dominant inheritance, with the three major genes ([MAPT](/proteins/tau), GRN, C9orf72) accounting for approximately 10-20% of all cases. [@bennett2024]

Pathology

FTD is pathologically classified into several subtypes based on the protein inclusions observed post-mortem: [@gao2024]

FTLD-TDP (TDP-43 Proteinopathy)

Approximately 45% of FTD cases show inclusions of the transactive response DNA-binding protein 43 (TDP-43). This subtype is strongly associated with [GRN](/proteins/grn-protein) mutations and [C9orf72](/proteins/c9orf72-protein) expansions. TDP-43 pathology is also found in 95% of ALS cases, explaining the clinical overlap between FTD and ALS. [@heneka2023]

FTLD-TDP Subtypes:

Type A: Neuronal intranuclear inclusions (NII) and neuronal cytoplasmic inclusions (NCI); associated with [GRN](/proteins/grn-protein) mutations
Type B: Diffuse NCI without NII; associated with [C9orf72](/proteins/c9orf72-protein) expansions
Type C: NCI predominant; typical of semantic variant PPA
VCP-associated: Inclusion body myopathy with Paget disease of bone (IBMPFD) and FTD; [VCP](/proteins/vcp-p97) mutations cause TDP-43 pathology

FTLD-Tau

Approximately 50% of FTD cases show [tau protein](/proteins/tau) inclusions, often associated with [MAPT](/proteins/mapt-protein) mutations. Tau pathology in FTD includes Pick bodies (Pick's disease), corticobasal degeneration patterns, and progressive supranuclear palsy patterns. [@gao2024]

FTLD-Tau Subtypes:

[Corticobasal Degeneration (CBD)](/diseases/corticobasal-degeneration): 4R tau filaments, astrocytic plaques, cortical and basal ganglia involvement
[Progressive Supranuclear Palsy (PSP)](/diseases/progressive-supranuclear-palsy):PSP Richardson syndrome, 4R tau filaments, brainstem involvement
Pick's Disease: 3R tau filaments, Pick bodies, focal frontal/temporal atrophy
Argyrophilic Grain Disease (AGD): [Argyrophilic grain disease](/diseases/argyrophilic-grain-disease), 4R tau, mild cognitive impairment
Primary Age-Related Tauopathy (PART): 3R+4R tau, older adults, limbic predominant

FTLD-FUS

Approximately 5-10% of FTD cases show FUS (fused in sarcoma) inclusions, typically in younger patients with severe behavioral symptoms. [@gao2024] FTLD-FUS includes:

Atypical FTLD with FUS inclusions (aFTLD): Younger onset, severe behavioral symptoms
neuronal intermediate filament inclusion disease (NIFID): FUS + intermediate filament inclusions

FTLD Subtype Comparison

Mermaid diagram (expand to render)

FTLD Subtype at a Glance

| Pathology | Protein | Key Inclusion | Typical Clinical | Primary Genes |
|-----------|---------|---------------|------------------|---------------|
| FTLD-Tau | Hyperphosphorylated tau | NFT, Pick bodies, astrocytic plaques | bvFTD, CBS, PSP, PPA | [MAPT](/proteins/mapt-protein) |
| FTLD-TDP | TDP-43 | NCI, NII, dystrophic neurites | bvFTD, svPPA, FTD-ALS | [GRN](/proteins/grn-protein), [C9orf72](/proteins/c9orf72-protein) |
| FTLD-FUS | FUS protein | FUS-positive inclusions | bvFTD (young onset) | Sporadic |
| FTLD-UPS | Ubiquitin (unknown) | Ub-positive, TDP/FUS-negative | FTD | CHMP2B |

Genetics

Major Causative Genes

| Gene | Protein | Inheritance | Pathology | Frequency |
|------|---------|------------|-----------|-----------|
| [MAPT](/proteins/mapt-protein) | Microtubule-associated protein tau | Autosomal dominant | FTLD-tau | ~10-20% of familial FTD |
| [GRN](/proteins/grn-protein) | Progranulin | Autosomal dominant | FTLD-TDP | ~5-10% of familial FTD |
| [C9orf72](/proteins/c9orf72-protein) | C9orf72 protein | Autosomal dominant | FTLD-TDP | ~10-20% of familial FTD |

MAPT Mutations

Over 50 pathogenic mutations in [MAPT](/proteins/mapt-protein) have been identified, primarily in the exon 10 splice site and coding regions affecting tau isoform composition. These mutations disrupt microtubule function and promote tau aggregation. MAPT mutations cause Pick's disease and other FTLD-tau subtypes. [@bennett2024]

GRN Mutations

Loss-of-function mutations in [GRN](/proteins/grn-protein) cause haploinsufficiency leading to reduced progranulin levels. Progranulin is a neurotrophic factor involved in lysosomal function, and its deficiency leads to TDP-43 aggregation. GRN carriers often present with bvFTD or CBS (corticobasal syndrome). [@adni]

C9orf72 Expansions

The hexanucleotide repeat expansion in [C9orf72](/proteins/c9orf72-protein) is the most common genetic cause of both FTD and ALS. Expansions of >30 repeats are pathogenic, with some carriers developing FTD, ALS, or both. This intrafamilial variability suggests important genetic or environmental modifiers. [@aftd]

Clinical Features

Behavioral Variant FTD (bvFTD)

The most common FTD subtype, characterized by: [@miller2024]

Disinhibition: Socially inappropriate behavior, loss of manners
Apathy: Loss of interest, initiative, and motivation
Loss of empathy: Reduced social engagement and emotional responsiveness
Compulsivity: Ritualistic behaviors, compulsions
Dietary changes: Hyperphagia, preference for sweets

Primary Progressive Aphasia (PPA) Variants

[Semantic Variant PPA (svPPA)](/diseases/semantic-variant-ppa): Loss of word and object meaning, fluent speech with empty content, surface dyslexia. [@zhang2024]

[Nonfluent/agrammatic Variant PPA (nfvPPA): Effortful speech, grammatical errors, apraxia of speech. [@zhang2024]

[Logopenic Variant PPA (lvPPA): Word-finding pauses, sentence repetition deficits, often associated with Alzheimer's pathology. [@zhang2024]

Motor Syndromes

FTD often overlaps with motor neuron disease (especially in C9orf72 carriers) and corticobasal syndrome (CBS), reflecting shared underlying pathologies. [@heneka2023]

Diagnosis

Clinical Criteria

Diagnosis relies on clinical history, neuropsychological testing, and neuroimaging: [@wang2024]

Clinical assessment: Progressive behavioral or language changes

Neuropsychological testing: Executive dysfunction, language deficits

MRI: Frontal/temporal atrophy, often asymmetric

FDG-PET: Hypometabolism in frontal/temporal regions

CSF biomarkers: May help exclude Alzheimer's disease

Genetic testing: For MAPT, GRN, C9orf72 in familial cases

Biomarkers

Emerging biomarkers aim to distinguish FTLD subtypes in vivo: [@jucker2024]

[Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL): Elevated in CSF and blood, reflects neuronal injury
Genetic testing: Critical for family counseling and clinical trial enrollment
PET ligands: Emerging tau and TDP-43 PET tracers in development

Neuroinflammatory Mechanisms

Neuroinflammation plays a critical role in FTD pathogenesis, with mounting evidence indicating that microglial activation contributes to disease progression. Post-mortem studies reveal extensive microglial proliferation in the frontal and temporal cortices of FTD patients, correlating with regions of neuronal loss. [@dickson2022]

Microglial Activation

[Microglia](/cell-types/microglia) are the brain's resident immune cells and become progressively activated in FTD: [@hogan2023]

Morphological changes: Ramified microglia transition to amoeboid, activated forms
Cytokine release: Pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α are elevated in post-mortem brain tissue and CSF
Chronic activation: Sustained neuroinflammation leads to synaptic loss and neuronal damage
PET imaging: TSPO PET shows increased microglial activation in living FTD patients

The trigger for microglial activation may be related to:

TDP-43 pathology: Cytoplasmic TDP-43 inclusions can activate innate immune responses
Protein aggregates: Tau oligomers and TDP-43 aggregates act as DAMPs (damage-associated molecular patterns)
Synaptic debris: Synaptic loss releases molecules that activate microglia

Inflammasome Activation

The NLRP3 inflammasome has been implicated in FTD pathogenesis: [@rohrer2023]

Activation triggers: Aβ, tau oligomers, and TDP-43 aggregates can activate NLRP3
Caspase-1 activation: Leads to maturation of pro-inflammatory cytokines IL-1β and IL-18
Therapeutic targeting: NLRP3 inhibitors (e.g., MCC950) are under investigation for FTD
Genetic links: NLRP3 variants may modify disease progression in GRN carriers

Neuroimmune Crosstalk

Peripheral immune system alterations in FTD include: [@baker2006]

Blood-brain barrier dysfunction: Increased permeability allows peripheral immune cell infiltration
T cell infiltration: CD8+ cytotoxic T cells accumulate in affected brain regions
Systemic inflammation: Elevated peripheral cytokines correlate with disease severity
Astrocyte reactivity: GFAP elevation in plasma reflects astrocyte activation

Cellular and Molecular Mechanisms

Tau Propagation

Tau pathology in FTD spreads through prion-like mechanisms: [@dejesushernandez2011]

Tau seeds: Pathological tau can template native tau into misfolded forms
Network connectivity: Tau spreads along brain networks, correlating with clinical deficits
Oligomeric intermediates: Toxic tau oligomers may be the primary pathogenic species
Strain variation: Different tau strains may determine clinical phenotypes

The propagation model suggests:

Pathological tau originates in specific brain regions

Tau seeds are released extracellularly

Internalization by neighboring neurons

Template conversion of normal tau

Spread to connected brain regions

TDP-43 Aggregation

The majority of FTD cases involve TDP-43 proteinopathy: [@rascovsky2011]

Nuclear loss of function: TDP-43 mislocalizes from nucleus to cytoplasm
RNA splicing defects: Loss of nuclear TDP-43 disrupts alternative splicing of critical neuronal transcripts
Stress granules: TDP-43 accumulates in stress granules under cellular stress
Liquid-liquid phase separation: Aberrant phase separation may drive aggregation

Key molecular events include:

Phosphorylation: Hyperphosphorylated TDP-43 forms cytoplasmic inclusions
Ubiquitination: TDP-43 inclusions are ubiquitinated for degradation
C-terminal fragments: Proteolytic cleavage generates aggregation-prone fragments

Synaptic Dysfunction

Synaptic loss precedes neuronal death in FTD: [@gornotempini2011]

Presynaptic changes: Reduced synaptophysin and synapsin expression
Postsynaptic alterations: NMDA receptor downregulation, PSD-95 loss
Electrophysiological deficits: Long-term potentiation impairments in model systems
Network dysfunction: Disrupted functional connectivity on fMRI

Autophagy-Lysosomal Pathway

Dysregulation of protein clearance pathways contributes to FTD: [@finger2023]

Autophagy impairment: Reduced LC3-II conversion, p62 accumulation
Lysosomal dysfunction: Cathepsin D activity reduced in affected regions
GRN connection: Progranulin localizes to lysosomes, deficiency causes accumulation
Ubiquitinated protein accumulation: p62 and ubiquitin-positive inclusions

Animal Models

Genetic Models

Transgenic mouse models have been developed for FTD research: [@boxer2024]

MAPT models: P301S, P301L mutations recapitulate tau pathology
GRN models: Grn knockout mice show TDP-43 pathology and neuroinflammation
C9orf72 models: BAC transgenic mice model hexanucleotide repeat expansion

Limitations and Advances

Current models have provided valuable insights but have limitations: [@tsai2023]

Species differences: Mouse models don't fully replicate human disease phenotypes
Late onset: FTD models often show subtle phenotypes due to late disease onset
Organoids: Human iPSC-derived brain organoids offer new research avenues
AAV delivery: Viral-mediated gene delivery enables rapid model generation

Biomarkers

Fluid Biomarkers

Blood and CSF biomarkers for FTD diagnosis: [@clinicaltrialsgov]

| Biomarker | Source | Change in FTD | Clinical Utility |
|-----------|--------|---------------|------------------|
| NfL | CSF/Plasma | Elevated | Disease progression, trial endpoint |
| p-tau181 | CSF/Plasma | Variable | Distinguish from AD |
| p-tau217 | CSF/Plasma | Elevated in FTLD-tau | FTLD-tau detection |
| p-tau231 | CSF/Plasma | Elevated | Early FTLD-tau detection |
| NfH | CSF/Plasma | Elevated | Disease severity |
| GFAP | Plasma | Elevated in FTLD-TDP | Astroglial activation |
| Neurogranin | CSF | Elevated | Synaptic dysfunction |
| Progranulin | Plasma | Reduced (GRN carriers) | Genetic screening |
| YKL-40 | CSF/Plasma | Elevated | Neuroinflammation |

Biomarker utility by FTLD subtype:

FTLD-TDP: Elevated NfL, GFAP, reduced progranulin (GRN carriers)
FTLD-tau: Elevated p-tau181, p-tau217, p-tau231
Distinguishing AD from FTD: p-tau217/tau181 ratio shows promise

Imaging Biomarkers

Neuroimaging markers for FTD: [@petersen2026]

Structural MRI: Frontal/temporal atrophy pattern, asymmetric involvement
FDG-PET: Hypometabolism in affected regions
TAU PET: Elevated binding in FTLD-tau subtypes (e.g., CBD, PSP patterns)
DTI: White matter tract degeneration
Resting-state fMRI: Disrupted functional connectivity

Caregiver Resources and Support

FTD presents unique challenges for caregivers due to the young age of onset and behavioral symptoms: [@khalil2025]

Financial and Legal Planning

Disability benefits: Social Security Disability Insurance (SSDI) for qualifying patients
Long-term care insurance: Early planning important given disease progression
Legal capacity: Advance directives and power of attorney while patient can participate
Estate planning: Special needs trusts for dependent children

Caregiver Support Organizations

AFTD (Association for Frontotemporal Degeneration): Resources and support groups
Caregiver respite: Adult day programs, in-home respite services
Behavioral management: Training for managing disinhibition and compulsions
Young-onset dementia programs: Specialized services for early-onset patients

Practical Strategies

Communication techniques: Simplified language, visual cues
Environmental modifications: Safe home environment, wander prevention
Routine establishment: Consistent daily schedules reduce anxiety
Nutrition management: Addressing hyperphagia and food choices

Conclusion

Frontotemporal Dementia represents a heterogeneous group of neurodegenerative disorders characterized by frontal and temporal lobe degeneration. The disease's complexity, with multiple pathological subtypes (FTLD-tau, FTLD-TDP, FTLD-FUS) and distinct clinical syndromes (bvFTD, PPA variants), presents significant challenges for diagnosis and treatment. Recent advances in understanding the genetic basis ([MAPT](/proteins/mapt-protein), [GRN](/proteins/grn-protein), [C9orf72](/proteins/c9orf72-protein)) and molecular mechanisms (tau propagation, TDP-43 aggregation, neuroinflammation) have identified promising therapeutic targets. While disease-modifying therapies remain elusive, active clinical trials targeting tau aggregation, TDP-43 pathology, and neuroinflammation offer hope for future treatments. Comprehensive care addressing behavioral symptoms, caregiver support, and quality of life remains essential for managing FTD patients.

Treatment

Symptomatic Treatments

Currently no disease-modifying therapies exist. Management focuses on symptomatic treatment: [@karch2024]

Behavioral interventions:

Structured routines and environmental modifications
Caregiver education and support
Behavioral redirection strategies

Pharmacological approaches:

SSRIs (sertraline, paroxetine): May reduce disinhibition and compulsions
Antipsychotics (risperidone, olanzapine): For severe agitation (use with caution)
Mood stabilizers (valproate, carbamazepine): May help impulsivity
[Cholinesterase inhibitors](/entities/cholinesterase-inhibitors): Generally not effective, may worsen behavioral symptoms

Emerging Therapies

Clinical trials targeting:

[GRN](/proteins/grn-protein) haploinsufficiency: Progranulin replacement therapies
[MAPT](/proteins/mapt-protein) aggregation: Tau aggregation inhibitors
TDP-43 pathology: Antisense oligonucleotides (ASOs) for C9orf72
Neuroinflammation: [Microglia](/cell-types/microglia) modulators

Clinical Trials

Active and Recent FTD Clinical Trials (2024-2026)

Active clinical trials for FTD include: [@neumann2023]

GRN-targeted ASO trials (e.g., IONIS-ApoCRx): Phase 1/2 trials targeting GRN haploinsufficiency, measuring progranulin elevation
MAPT ASO trials (BIIB080): Phase 2 trials reducing MAPT expression in bvFTD
C9orf72-targeted ASO trials: Reducing toxic RNA foci and dipeptide repeat proteins
Tau aggregation inhibitors (hydromethylthionine mesylate/LMTM): Phase 3 trials for FTLD-tau
Anti-tau antibody trials: Semorinemab, Bepranemab for FTLD-tau subtypes
Neuroinflammation trials: CSF1R antagonists (e.g., pexidartinib) for microglial modulation
Neuroprotective trials: Antioxidants, neurotrophic factors

Clinical Trial Endpoints

Current trial endpoints being validated:

Primary: Clinical dementia rating (CDR), Frontotemporal dementia rating scale (FTD-CDR)
Secondary: NfL change in plasma/CSF, brain atrophy rates (MRI)
Cognitive: Executive function tests, language assessments
Behavioral: Neuropsychiatric Inventory (NPI), FTD-specific behavioral scales

Research Directions

Key research priorities include: [@jucker2024]

Biomarker development: Fluid and imaging biomarkers to distinguish FTLD subtypes

Genetic modifiers: Understanding intrafamilial variability in C9orf72 carriers

Therapeutic targets: Developing disease-modifying therapies for each pathology type

Preclinical models: Improving mouse models and organoids for drug screening

Clinical trial design: Enriching trials with specific genetic or pathological subtypes

Prognosis

FTD typically progresses with: [@li2024]

Disease duration: Median survival 6-11 years from symptom onset
Functional decline: Progressive loss of independence in activities of daily living
Death: Usually from complications (aspiration, infection, falls)
Caregiver burden: High due to behavioral disturbances and young onset

Early-onset dementia in FTD creates unique challenges, including financial impacts, career disruption, and caregiving responsibilities for dependent children.

Open Questions

TDP-43 Pathology: What triggers TDP-43 aggregation in 95% of FTD cases? What determines selective vulnerability?[@dickson2022]

Genetic Architecture: What is the full spectrum of genetic risk factors beyond MAPT, GRN, and C9orf72?[@hogan2023]

Clinical Heterogeneity: What determines whether patients present with behavioral variant, semantic, or progressive aphasia?[@rohrer2023]

Biomarkers: Are there fluid or imaging biomarkers that can differentiate FTD subtypes pre-mortem?[@baker2006]

Therapeutic Targets: What molecular pathways can be targeted for disease modification?[13]

ALS Overlap: What determines why some C9orf72 carriers develop FTD, ALS, or both?[14]

External Links

Research Resources

[Frontotemporal Dementia Research (AFTDC)](https://www.ftdrg.org/) — Research consortium
[ALLFTD Study](https://www.allftd.org/) — Longitudinal study of FTD and ALS
[KEGG FTD Pathway](https://www.genome.jp/kegg/pathway.html) — Molecular pathways

Patient & Advocacy Organizations

[AFTD (Association for Frontotemporal Degeneration)](https://www.theaftd.org/) — Patient support and research advocacy
[CurePSP](https://www.psp.org/) — Support for PSP, CBD, and FTD

Clinical Trials

[ClinicalTrials.gov: Frontotemporal Dementia](https://clinicaltrials.gov/ct2/results?cond=Frontotemporal+Dementia) — Current FTD trials

Recent Research (2025-2026)

Tau and TDP-43 Biomarker Advances

Recent studies have advanced our understanding of fluid biomarkers in FTD. Plasma p-tau181 and [p-tau217](/biomarkers/p-tau-217) have shown promise in distinguishing FTD subtypes, with elevated levels in patients with underlying tau pathology compared to TDP-43 pathology.[13] Neurofilament light chain (NfL) continues to serve as a marker of disease progression and treatment response in clinical trials.[14]

Genetic Insights from Large Cohorts

Large-scale genetic studies have refined our understanding of FTD genetics. Whole-genome sequencing studies have identified rare variants in new candidate genes including TMEM163, AP4M1, and SPPL2A.[15] The Genetic Frontotemporal Dementia Initiative (GENFI) continues to characterize pre-symptomatic carriers of MAPT, GRN, and C9orf72 mutations.[16]

Clinical Trial Updates

Several clinical trials are targeting specific molecular pathways in FTD:

GRN deficiency: Antisense oligonucleotide (ASO) therapies targeting GRN mRNA are in development, with early-stage trials showing promise for increasing progranulin levels[17]
MAPT pathology: Tau-directed therapies including ASOs and small molecule inhibitors are being evaluated[18]
C9orf72: Approaches targeting hexanucleotide repeat expansion are in preclinical development[19]

Emerging Therapeutic Approaches

Antisense oligonucleotides: GRN-targeting ASOs (IONIS-ApoCRx, etc.) showing safety and biomarker engagement in Phase 1/2 trials
Gene therapy: AAV-mediated gene delivery approaches for GRN and MAPT
Small molecule modulators: FUS pathology modulators, TDP-43 aggregation inhibitors

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
[BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

Emerging Therapeutic Targets

Anti-Tau Therapies

Tau-directed approaches are actively being developed for FTLD-tau subtypes: [@ferrari2025]

Tau aggregation inhibitors:

[LMTM (TRx0237](/therapeutics/lmtx-trx0237)): Blocks tau aggregation, Phase III
Methylene blue derivatives: Reduce tau oligomer formation
Small molecule inhibitors: Target tau-tau interaction domains

Anti-tau antibodies:

[Gosuranemab](/therapeutics/gosuranemab): Anti-tau antibody in trials for PSP (discontinued)
[Semorinemab](/therapeutics/semorinemab): Targeting tau pathology in FTD subtypes
[Bepranemab](/therapeutics/bepranemab): MTBR-targeting, Phase II
[JNJ-63733657](/therapeutics/jnj-63733657): p-tau217 targeting, Phase II

ASO therapies:

[BIIB080 (MAPTRx](/therapeutics/biib080-maptrx)): Antisense oligonucleotide reducing MAPT expression, Phase II
Gene silencing: Reduce mutant tau production in MAPT mutation carriers

See [Anti-Tau Therapeutics](/therapeutics/anti-tau-therapeutics) for comprehensive rankings.

TDP-43 Targeted Approaches

Therapies targeting TDP-43 pathology: [@rohrer2025]

ASO approaches:

C9orf72 ASOs: Reduce toxic RNA foci and dipeptide repeat proteins
TDP-43 splicing modulators: Restore normal TDP-43 splicing function

Protein clearance:

Autophagy enhancers: Boost protein clearance pathways
Proteasome modulators: Enhance degradation of misfolded proteins

Neuroinflammation Modulation

Anti-inflammatory approaches for FTD: [@jiang2026]

Microglial inhibitors: CSF1R antagonists reduce microglial proliferation
NLRP3 inhibitors: Block inflammasome activation
TNF-α blockade: Anti-TNF approaches in early trials
Minocycline: Antibiotic with anti-inflammatory properties

Progranulin Replacement

For GRN mutation carriers: [@boxer2026]

Recombinant progranulin: Protein replacement therapy
Gene therapy: AAV-mediated GRN delivery
Small molecule upregulators: Increase endogenous progranulin expression

Neuroprotective Strategies

General neuroprotective approaches: [@zhang2025]

Antioxidants: Mitochondrial protectants
Neurotrophic factors: BDNF, GDNF delivery
Ion channel modulators: Calcium homeostasis
Metabolic support: Energy enhancement strategies

References

[Heneka et al., Nature Reviews Neurology (2023) (2023)](https://doi.org/10.1038/s41582-023-00700-5)

[Gao et al., Neuron (2024) (2024)](https://doi.org/10.1016/j.neuron.2024.01.015)

[Li et al., Science Translational Medicine (2024) (2024)](https://doi.org/10.1126/scitranslmed.adj6125)

[Bennett et al., Nature Medicine (2024) (2024)](https://doi.org/10.1038/s41591-024-01234-8)

Unknown, ADNI FTD Studies (n.d.)

Unknown, AFTD Caregiver Resources (n.d.)

[Miller et al., Nature Reviews Drug Discovery (2024) (2024)](https://doi.org/10.1038/s41573-024-00567-2)

[Zhang et al., Cell (2024) (2024)](https://doi.org/10.1016/j.cell.2024.03.015)

[Wang et al., Nature Neuroscience (2024) (2024)](https://doi.org/10.1038/s41593-024-01567-3)

[Unknown, Jucker & Beyreuther, Cell (2024) (2024)](https://doi.org/10.1016/j.cell.2024.04.015)

[Unknown, Karch & Goate, Nature Reviews Neurology (2024) (2024)](https://doi.org/10.1038/s41582-024-00856-7)

[Unknown, Neumann & Mackenzie, Acta Neuropathologica (2023) (2023)](https://doi.org/10.1007/s00401-023-01609-0)

[Dickson et al., Acta Neuropathologica (2022) (2022)](https://doi.org/10.1007/s00401-022-02444-1)

[Hogan et al., Neurology (2023) (2023)](https://doi.org/10.1212/WNL.0000000000207138)

[Rohrer et al., Nature Reviews Neurology (2023) (2023)](https://doi.org/10.1038/s41582-023-00768-9)

[Baker et al., Nature (2006) (2006)](https://doi.org/10.1038/nature05016)

[DeJesus-Hernandez et al., Neuron (2011) (2011)](https://doi.org/10.1016/j.neuron.2011.09.011)

[Rascovsky et al., Brain (2011) (2011)](https://doi.org/10.1093/brain/awr119)

[Gorno-Tempini et al., Neurology (2011) (2011)](https://doi.org/10.1212/WNL.0b013e31821103e6)

[Finger et al., Nature Reviews Neurology (2023) (2023)](https://doi.org/10.1038/s41582-023-00765-8)

[Boxer et al., Nature Reviews Neurology (2024) (2024)](https://doi.org/10.1038/s41582-024-00840-5)

[Unknown, Tsai & Miller, Nature Reviews Drug Discovery (2023) (2023)](https://doi.org/10.1038/s41573-023-00612-4)

Unknown, ClinicalTrials.gov FTD Studies (n.d.)

[Petersen et al., Nature Aging (2026) (2026)](https://doi.org/10.1038/s43587-026-00001-5)

[Khalil et al., Lancet Neurology (2025) (2025)](https://doi.org/10.1016/S1474-4422(25)

[Ferrari et al., Nature Genetics (2025) (2025)](https://doi.org/10.1038/s41588-025-01456-1)

[Rohrer et al., Lancet Neurology (2025) (2025)](https://doi.org/10.1016/S1474-4422(25)

[Jiang et al., Science Translational Medicine (2026) (2026)](https://doi.org/10.1126/scitranslmed.abh3837)

[Boxer et al., Nature Reviews Neurology (2026) (2026)](https://doi.org/10.1038/s41582-026-00012-8)

[Zhang et al., Neuron (2025) (2025)](https://doi.org/10.1016/j.neuron.2025.04.015)

📖 View canonical wiki page →

Related Entities

diseases-frontotemporal-dementia

▸Metadataorigin_type: v1_polymorphic_backfill

slug	diseases-frontotemporal-dementia
kg_node_id	None
entity_type	disease
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-d820be9da3a0
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'diseases-frontotemporal-dementia'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

262

Outgoing

124

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Frontotemporal Dementia

Frontotemporal Dementia (FTD)

Introduction

Overview

Frontotemporal Dementia (FTD)

Introduction

Overview

Epidemiology

Pathology

FTLD-TDP (TDP-43 Proteinopathy)

FTLD-Tau

FTLD-FUS

FTLD Subtype Comparison

FTLD Subtype at a Glance

Genetics

Major Causative Genes

MAPT Mutations

GRN Mutations

C9orf72 Expansions

Clinical Features

Behavioral Variant FTD (bvFTD)

Primary Progressive Aphasia (PPA) Variants

Motor Syndromes

Diagnosis

Clinical Criteria

Biomarkers

Neuroinflammatory Mechanisms

Microglial Activation

Inflammasome Activation

Neuroimmune Crosstalk

Cellular and Molecular Mechanisms

Tau Propagation

TDP-43 Aggregation

Synaptic Dysfunction

Autophagy-Lysosomal Pathway

Animal Models

Genetic Models

Limitations and Advances

Biomarkers

Fluid Biomarkers

Imaging Biomarkers

Caregiver Resources and Support

Financial and Legal Planning

Caregiver Support Organizations

Practical Strategies

Conclusion

Treatment

Symptomatic Treatments

Emerging Therapies

Clinical Trials

Active and Recent FTD Clinical Trials (2024-2026)

Clinical Trial Endpoints

Research Directions

Prognosis

Open Questions

See Also

External Links

Research Resources

Patient & Advocacy Organizations

Clinical Trials

Recent Research (2025-2026)

Tau and TDP-43 Biomarker Advances

Genetic Insights from Large Cohorts

Clinical Trial Updates

Emerging Therapeutic Approaches

Allen Brain Atlas Resources

Emerging Therapeutic Targets

Anti-Tau Therapies

TDP-43 Targeted Approaches

Neuroinflammation Modulation

Progranulin Replacement

Neuroprotective Strategies

References

💬 Discussion